^
    Back
    Association details:
    Biomarker:JAK2 mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:LY3009120 (pan-RAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2018
    Title:

    Paradox-Breaker Pan-RAF Inhibitors Induce an AML-Specific Cytotoxic Response and Synergize with Venetoclax to Display Superior Antileukemic Activity

    Published date:
    11/01/2019
    Excerpt:
    ...explored the link between somatic mutation status and response to LY3009120 in our AML patient sample cohort. KRAS, KIT, FLT3-TKD, BCOR, JAK2 and PTPN11 mutations were found to correlate positively with pan-RAF inhibitor response, while SRSF2, RUNX1, GATA2 and STAG2 mutations negatively correlated with response and appeared to override positively correlating mutations.
    DOI:
    10.1182/blood-2018-99-118289